Active ingredient
- buprenorphine
Legal Category
POM: Prescription only medicine
POM: Prescription only medicine
The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. It is written for patients and gives information about taking or using a medicine. It is possible that the leaflet in your medicine pack may differ from this version because it may have been updated since your medicine was packaged.
Below is a text only representation of the Patient Information Leaflet. The original leaflet can be viewed using the link above.
The text only version may be available in large print, Braille or audio CD. For further information call emc accessibility on 0800 198 5000. The product code(s) for this leaflet is: PL 25258/0178.
Bunov 5, 10, 20 microgram/h transdermal patch
Package leaflet: Information for the patient
Bunov 5 microgram/h transdermal patch
Bunov 10 microgram/h transdermal patch
Bunov 20 microgram/h transdermal patch
buprenorphine
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
What is in this leaflet
1. What Bunov is and what it is used for
2. What you need to know before you use Bunov
3. How to use Bunov
4. Possible side effects
5. How to store Bunov
6. Contents of the pack and other information
1. What Bunov is and what it is used for
Bunov contain the active ingredient buprenorphine which belongs to a group of medicines called strong analgesics or ‘painkillers’. They have been prescribed for you by your doctor to relieve moderate, long-lasting pain that requires the use of a strong painkiller.
Bunov should not be used to relieve acute pain.
Bunov patches act through the skin. After application, buprenorphine passes through the skin into the blood. Each patch lasts for seven days.
2. What you need to know before you use Bunov
Do not use Bunov:
Bunov must not be used to treat symptoms associated with drug withdrawal.
Warnings and precautions
Talk to your doctor or pharmacist before using Bunov:
If you have recently had an operation, please speak to your doctor before using these patches.
Athletes should be aware that this medicine may cause a positive reaction to sports doping control tests.
Sleep-related breathing disorders
Bunov can cause sleep-related breathing disorders such as sleep apnoea (breathing pauses during sleep) and sleep related hypoxemia (low oxygen level in the blood). The symptoms can include breathing pauses during sleep, night awakening due to shortness of breath, difficulties to maintain sleep or excessive drowsiness during the day. If you or another person observe these symptoms, contact your doctor. A dose reduction may be considered by your doctor.
Children and adolescents
Do not give this medicine to children and adolescents below 18 years.
Other medicines and Bunov
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Concomitant use of Bunov and sedative medicines such as benzodiazepines or related drugs increases the risk of drowsiness, difficulties in breathing (respiratory depression), coma and may be life-threatening. Because of this, concomitant use should only be considered when other treatment options are not possible.
However if your doctor does prescribe Bunov together with sedative medicines the dose and duration of concomitant treatment should be limited by your doctor.
Please tell your doctor about all sedative medicines you are taking, and follow your doctor’s dose recommendation closely. It could be helpful to inform friends or relatives to be aware of the signs and symptoms stated above. Contact your doctor when experiencing such symptoms.
Bunov with alcohol
Alcohol may make some of the side effects worse and you may feel unwell if you drink alcohol whilst wearing Bunov. Drinking alcohol whilst using Bunov may also affect your reaction time.
Pregnancy, breast-feeding and fertility
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.
Pregnancy
There is not sufficient experience regarding the use of buprenorphine in pregnant women. Therefore you should not use Bunov if you are pregnant or if you could become pregnant during treatment.
Breast-feeding
Buprenorphine, the active substance contained in the transdermal patch, may inhibit milk formation and passes into the breast milk. Therefore, you should not use Bunov if you are breast-feeding.
Driving and using machines
Bunov may affect your reactions to such an extent that you may not react adequately or quickly enough in the event of unexpected or sudden occurrences. This applies particularly:
Bunov can affect your ability to drive as it may make you sleepy or dizzy.
Talk to your doctor or pharmacist if you are not sure whether it is safe for you to drive while taking this medicine.
If you are affected (e.g. feel dizzy, drowsy or have blurred vision), you should not drive or operate machinery whilst using Bunov, or for 24 hours after removing the patch.
3. How to use Bunov
Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
Different strengths of Bunov are available. Your doctor will decide which strength of Bunov will suit you best.
When people first start using Bunov, they often experience some nausea and vomiting (see section 4). This usually passes after the first week of treatment. It’s a good idea to book a follow-up appointment with your doctor a week or two after you first start using Bunov patches to ensure that you are taking the correct dose and to manage any side effects.
During treatment, your doctor may change the patch you use to a smaller or larger one if necessary. Do not cut or divide the patch or use a higher dose than recommended. You should not apply more than two patches at the same time, up to a maximum total dose of 40 micrograms/hour.
If you feel that the effect of the Bunov is too weak or too strong, talk to your doctor or pharmacist.
Adults and elderly patients
Unless your doctor has told you differently, attach one Bunov patch (as described in detail below) and change it every seventh day, preferably at the same time of day. Your doctor may wish to adjust the dose after 3-7 days until the correct level of pain control has been found. If your doctor has advised you to take other painkillers in addition to the patch, strictly follow the doctor’s instructions, otherwise you will not fully benefit from treatment with Bunov. The patch should be worn for 3 full days before increasing the dose, this is when the maximum effect of a given dose is established.
Patients with kidney disease/dialysis patients
In patients with kidney disease, no change in dose is necessary.
Patients with liver disease
In patients with liver disease, the effects and period of action of the Bunov may be affected and your doctor will therefore check on you more closely.
Patients under 18 years of age
Bunov should not be used in patients below the age of 18 years.
Method of administration
Bunov transdermal patch is for transdermal use.
Bunov act through the skin. After application, buprenorphine passes through the skin into the blood.
Before applying the transdermal patch
Applying the transdermal patch
Wearing the transdermal patch
You should wear the patch for seven days. Provided that you have applied the patch correctly, there is little risk of it coming off. If the edges of the patch begin to peel off, they may be taped down with a suitable skin tape. You may shower, bathe or swim whilst wearing it.
Do not expose the patch to extreme heat (e.g. heating pads, electric blanket, heat lamps, sauna, hot tubs, heated water beds, hot water bottle, etc) as this may lead to larger quantities of the active ingredient being absorbed into the blood than normal. External heat may also prevent the patch from sticking properly. If you have a high temperature this may alter the effects of Bunov (see “Warnings and precautions” section above).
In the unlikely event that your patch falls off before it needs changing, do not use the same patch again. Stick a new one on straight away (see “Changing the transdermal patch” below).
Changing the transdermal patch
Duration of treatment
Your doctor will tell you how long you should be treated with the Bunov. Do not stop treatment without consulting a doctor, because your pain may return and you may feel unwell (see also “If you stop using Bunov” below).
If you use more Bunov than you should
As soon as you discover that you have used more patches than you should, remove all patches and call your doctor or hospital straight away. People who have taken an overdose may feel very sleepy and sick. They may also have breathing difficulties or lose consciousness and may need emergency treatment in hospital. When seeking medical attention make sure that you take this leaflet and any remaining patches with you to show to the doctor.
If you forget to use Bunov
Stick a new patch on as soon as you remember. Also make a note of the date, as your usual day of changing may now be different. If you are very late changing your patch, your pain may return. In this case, please contact your doctor.
Do not apply additional patches to make up for the forgotten application.
If you stop using Bunov
If you stop using Bunov too soon or you interrupt your treatment your pain may return. If you wish to stop treatment please consult your doctor. They will tell you what can be done and whether you can be treated with other medicines.
Some people may have side effects when they have used strong painkillers for a long time and stop using them. The risk of having effects after stopping Bunov is very low. However, if you feel agitated, anxious, nervous or shaky, if you are overactive, have difficulty sleeping or digestive problems, tell your doctor.
The pain relieving effect of Bunov is maintained for some time after removal of the patch. You should not start another opioid analgesic (strong painkiller) within 24 hours after removal of the patch.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Serious side effects that may be associated with Bunov are similar to those seen with other strong painkillers and include difficulty in breathing and low blood pressure.
This medicine can cause allergic reactions, although serious allergic reactions are rare. Remove the patch and tell your doctor immediately if you get any sudden wheeziness, difficulties in breathing, swelling of the eyelids, face or lips, rash or itching especially those covering your whole body.
There is a risk that you may become addicted or reliant on Bunov.
In patients treated with buprenorphines, the following other side effects have been reported:
Very common (may affect more than 1 in 10 people):
Common (may affect up to 1 in 10 people):
Uncommon (may affect up to 1 in 100 people):
If you need to have blood tests remind your doctor that you are using Bunov. This is important because Bunov may change the way your liver works and this could affect the results of some blood tests.
Rare (may affect up to 1 in 1,000 people):
Very rare (may affect up to 1 in 10,000 people):
Not known (frequency cannot be estimated from the available data):
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store.
By reporting side effects, you can help provide more information on the safety of this medicine.
5. How to store Bunov
6. Contents of the pack and other information
What Bunov patches contain
[5 microgram/h:]
Each transdermal patch contains 5 mg of buprenorphine in a patch size of 6.25 cm2 and releases 5 micrograms of buprenorphine per hour (over a period of 7 days).
[10 microgram/h:]
Each transdermal patch contains 10 mg of buprenorphine in a patch size of 12.5 cm2 and releases 10 micrograms of buprenorphine per hour (over a period of 7 days).
[20 microgram/h:]
Each transdermal patch contains 20 mg of buprenorphine in a patch size of 25 cm2 and releases 20 micrograms of buprenorphine per hour (over a period of 7 days).
Adhesive matrix (containing buprenorphine): povidone K90, levulinic acid, oleyl oleate, Poly[acrylic acid-co-butylacrylate-co-(2-ethylhexyl)acrylate-co-vinylacetate] (5:15:75:5)
Adhesive matrix (without buprenorphine): Poly[(2-ethylhexyl)acrylate-co-glycidylmethacrylate-co-( 2-hydroxyethyl)acrylate-co-vinylacetate] (68:0,15:5:27),
Separating foil between adhesive matrices with and without buprenorphine: Polyethylene terephthalate film,
Backing foil: polyester,
Release liner: Polyethylene terephthalate film, siliconised
Blue printing ink
What Bunov look like and contents of the pack
Transdermal patch
Three sizes are available.
[5 microgram/h:]
Each transdermal patch is beige coloured with rounded corners and is imprinted with “Buprenorphin” and “5 μg/h”
[10 microgram/h:]
Each transdermal patch is beige coloured with rounded corners and is imprinted with “Buprenorphin” and “10 μg/h”
[20 microgram/h:]
Each transdermal patch is beige coloured with rounded corners and is imprinted with “Buprenorphin” and “20 μg/h”
One transdermal patch is sealed in one child-resistant sachet. The patches are available in cartons containing
2, 4, 5, 8 or 12 transdermal patches.
Not all pack sizes may be marketed.
Marketing Authorisation Holder
Manufacturer
This leaflet was last revised in June 2021
Building 2, 1st Floor, Croxley Park, Watford, WD18 8YA
+44 (0)1923 202 950
+44 (0)1923 202 950